{
 "as_of": "2026-11-06",
 "cmr": "ca-cm-kg/TSXV/NRX",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# NurExone Biologic Inc. (TSXV: NRX) — research page\n\nAs of 2026-11-06 · ca-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is NurExone Biologic Inc., listed on the TSXV under ticker NRX. Its ISIN is CA67059R1091 and its LEI is 25490047UWNZ2P8ESB77. Its security type is Corporate, its sector is Life Sciences, and its jurisdiction is Ontario, Canada. Its segment is not on the record. Its listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 9 filings in the twelve months to 2026-11-06, on 9 filing days. Of these, 3 are exchange bulletins and 6 are newswire releases. The median gap between filing days is 10.5 days. The latest filing is dated 2026-10-30 and is a newswire release, 7 days before the record date. The exchange median is 19 days cadence, 9 filings and 17.0 days latency across 1427 TSXV issuers. The sector median is 17.5 days cadence, 7.0 filings and 14 days latency across 200 Life Sciences issuers.\n\n## Auditor\n\nThe auditor is not on the record, as none was found. Its location is not on the record. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting, name change, domicile change or segment move events. The issuer is listed, not halted.\n\n## Orderability\n\nUnder rule version acm-68000/ca/kyp-know-your-product-ni-31-103/r1, as of 2026-11-04, the outcome is determinable for both client categories. Paragraph (o) of the definition and paragraph (q) of the definition each carry signal ACM-200.\n\n## Coverage\n\nThe issuer's investor-relations page names 7 research houses: Zacks Small Cap Research, Poschevale Securities, Tormont Group LLC, Fundamental Research Corp., Litchfield Hills Research LLC, Morningstar and WTR.\n\n## Open research\n\nThe record holds 5 openly published research notes. Water Tower Research LLC published on 2026-05-21 and 2026-04-21. Zacks Small-Cap Research published on 2025-07-09. Poschevale Securities published on 2025-03-01 and 2024-07-01.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe market's vintage is not sealed. The record holds no sealed issuer years, and the market has no earliest sealed date. The live record began on 2026-09-10. The store holds sealed years 2021 through 2026 for this issuer, but these are not served as of a date, and the as-of answer is not_sealed.\n\n## Sources\n\n14 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.tsx.com/json/company-directory/search/tsxv/^* (identity.exchange)\n- https://www.marketscreener.com/quote/stock/NUREXONE-BIOLOGIC-INC-139971056/finances (identity.isin)\n- https://api.gleif.org/api/v1/lei-records/25490047UWNZ2P8ESB77 (identity.jurisdiction)\n- https://www.tsx.com/en/resource/571 (identity.sector)\n- https://mcp.ca-cm-kg.ai/events/TSXV/NRX (the disclosure lines)\n- https://iiroc.mediaroom.com/index.php?s=2429&l=100 (the halt flag)\n- https://mcp.ca-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://nurexone.com/investors/ (coverage)\n- https://nurexone.com/wp-content/uploads/2026/05/NRX-Initiating-Coverage_-A-Novel-Exosome-Platform-at-the-Frontier-of-CNS-Regeneration-May-21-2026.pdf (open research)\n- https://nurexone.com/wp-content/uploads/2026/04/MS_NRX-From-Preclinical-Promise-to-Clinical-Execution-De-Risking-the-Exosome-Opportunity-in-CNS-April-21-2026.pdf (open research)\n- https://nurexone.com/wp-content/uploads/2025/07/Zacks_SCR_Research_07092025_NRXBF_Sorensen.pdf (open research)\n- https://nurexone.com/wp-content/uploads/2025/04/Nurexone_Biologic_Inc_Poschevale_Report_March_2025_1743438611.pdf (open research)\n- https://nurexone.com/wp-content/uploads/2024/08/Analyst-Report-on-NurExone.pdf (open research)\n- https://mcp.ca-cm-kg.ai/record/TSXV/NRX (the record)\n",
 "market": "CA",
 "node": "ca-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [],
   "live_record_began": "2026-09-10",
   "node_history_from": null,
   "node_years_sealed": [],
   "note": "6 years are sealed in the CA store; their Replay split is not built, so the as-of door answers not_sealed and the record is the live record as of 2026-11-06",
   "record_version": 1,
   "sealed": false,
   "store_years_sealed_not_served": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ]
  },
  "auditor": {
   "auditor": {
    "market": "CA",
    "reason": "none found",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "CA",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "CA",
    "state": "not_on_record"
   },
   "changes": []
  },
  "cmr": "ca-cm-kg/TSXV/NRX",
  "coverage": {
   "count": 7,
   "houses": [
    {
     "house": "Zacks Small Cap Research",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://nurexone.com/investors/",
     "state": "sourced"
    },
    {
     "house": "Poschevale Securities",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://nurexone.com/investors/",
     "state": "sourced"
    },
    {
     "house": "Tormont Group LLC",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://nurexone.com/investors/",
     "state": "sourced"
    },
    {
     "house": "Fundamental Research Corp.",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://nurexone.com/investors/",
     "state": "sourced"
    },
    {
     "house": "Litchfield Hills Research LLC",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://nurexone.com/investors/",
     "state": "sourced"
    },
    {
     "house": "Morningstar",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://nurexone.com/investors/",
     "state": "sourced"
    },
    {
     "analyst": "Robert Sassoon",
     "house": "WTR",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://nurexone.com/investors/",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://nurexone.com/investors/",
     "result": "read: 7 of 9 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-12",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 1427,
     "median_cadence_gap_days": 19,
     "median_filings": 9,
     "median_latency_days": 17,
     "name": "TSXV"
    },
    "sector": {
     "issuers": 200,
     "median_cadence_gap_days": 17.5,
     "median_filings": 7,
     "median_latency_days": 14,
     "name": "Life Sciences"
    }
   },
   "by_type": {
    "exchange_bulletin": 3,
    "newswire_release": 6
   },
   "cadence_median_gap_days": 10.5,
   "filing_days": 9,
   "filings": 9,
   "latency_days": 7,
   "latest": [
    {
     "category": null,
     "date": "2026-10-30",
     "source": "https://www.globenewswire.com/news-release/2026/10/30/3392203/0/en/nurexone-demonstrates-consistent-anti-inflammatory-activity-across-three-separate-batches-of-exosomes.html",
     "title": "NurExone Demonstrates Consistent Anti-Inflammatory Activity",
     "type": "newswire_release"
    },
    {
     "category": null,
     "date": "2026-10-22",
     "source": "https://www.globenewswire.com/news-release/2026/10/22/3386349/0/en/nurexone-demonstrates-scalable-exosome-production-supporting-its-modular-manufacturing-strategy-and-commercial-growth.html",
     "title": "NurExone Demonstrates Scalable Exosome Production,",
     "type": "newswire_release"
    },
    {
     "category": null,
     "date": "2026-10-09",
     "source": "https://www.globenewswire.com/news-release/2026/10/09/3378353/0/en/nurexone-advances-optic-nerve-injury-program-toward-larger-animal-study-following-positive-preclinical-results.html",
     "title": "NurExone Advances Optic Nerve Injury Program Toward",
     "type": "newswire_release"
    },
    {
     "category": null,
     "date": "2026-09-18",
     "source": "https://www.globenewswire.com/news-release/2026/09/18/3364949/0/en/nurexone-expands-u-s-engagement-across-four-major-boston-life-sciences-events-and-provides-corporate-update.html",
     "title": "NurExone Expands U.S. Engagement Across Four Major Boston",
     "type": "newswire_release"
    },
    {
     "category": null,
     "date": "2026-09-16",
     "source": "https://www.globenewswire.com/news-release/2026/09/16/3363531/0/en/nurexone-announces-voting-results-of-annual-general-and-special-meeting-of-shareholders-and-provides-corporate-update.html",
     "title": "NurExone Announces Voting Results of Annual General and",
     "type": "newswire_release"
    }
   ],
   "latest_filing_date": "2026-10-30",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.ca-cm-kg.ai/events/TSXV/NRX",
   "window": {
    "from": "2025-11-06",
    "to": "2026-11-06"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "tsx.com company directory (exchange list)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.tsx.com/json/company-directory/search/tsxv/^*",
    "state": "sourced",
    "value": "TSXV"
   },
   "isin": {
    "read_by": "Tavily search + regex extraction from page text",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.marketscreener.com/quote/stock/NUREXONE-BIOLOGIC-INC-139971056/finances",
    "state": "confirmed",
    "value": "CA67059R1091"
   },
   "jurisdiction": {
    "read_by": "GLEIF LEI record (LEI per the LEI column) · adjudicated by Claude",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://api.gleif.org/api/v1/lei-records/25490047UWNZ2P8ESB77",
    "state": "filled",
    "value": "Ontario, Canada"
   },
   "lei": {
    "read_by": "GLEIF name-exact",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://api.gleif.org/api/v1/lei-records/25490047UWNZ2P8ESB77",
    "state": "filled",
    "value": "25490047UWNZ2P8ESB77"
   },
   "name": {
    "read_by": "tsx.com company directory (exchange list)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.tsx.com/json/company-directory/search/tsxv/^*",
    "state": "sourced",
    "value": "NurExone Biologic Inc."
   },
   "sector": {
    "read_by": "TMX listed-companies workbook (exchange list, monthly; data month named in the source column)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.tsx.com/en/resource/571 (tsx-and-amp-tsxv-listed-companies-2026-08-14-en.xlsx, data as of 31-Jul-2026)",
    "state": "sourced",
    "value": "Life Sciences"
   },
   "security_type": {
    "read_by": "TMX listed-companies workbook (exchange list, monthly; data month named in the source column)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.tsx.com/en/resource/571 (tsx-and-amp-tsxv-listed-companies-2026-08-14-en.xlsx, data as of 31-Jul-2026)",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "CA",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "tsx.com company directory (exchange list)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.tsx.com/json/company-directory/search/tsxv/^*",
    "state": "sourced",
    "value": "NRX"
   },
   "website": {
    "market": "CA",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": [],
   "listing": [],
   "name_change": [],
   "segment_move": []
  },
  "market": "CA",
  "node": "ca-cm-kg",
  "numbers_hash": "sha256:1e7079675e903e065894f84908781cd7ca26fa29793353cc4fc7240ed18b4966",
  "open_research": {
   "read_date": "2026-11-12",
   "rows": [
    {
     "date": "2026-05-21",
     "kind": "issuer-sponsored",
     "publisher": "Water Tower Research LLC",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://nurexone.com/wp-content/uploads/2026/05/NRX-Initiating-Coverage_-A-Novel-Exosome-Platform-at-the-Frontier-of-CNS-Regeneration-May-21-2026.pdf",
     "state": "sourced",
     "title": "NRX: Initiating Coverage; A Novel Exosome Platform at the Frontier of CNS Regeneration"
    },
    {
     "date": "2026-04-21",
     "kind": "issuer-sponsored",
     "publisher": "Water Tower Research LLC",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://nurexone.com/wp-content/uploads/2026/04/MS_NRX-From-Preclinical-Promise-to-Clinical-Execution-De-Risking-the-Exosome-Opportunity-in-CNS-April-21-2026.pdf",
     "state": "sourced",
     "title": "NRX: From Preclinical Promise to Clinical Execution - De-Risking the Exosome Opportunity in CNS"
    },
    {
     "date": "2025-07-09",
     "kind": "issuer-sponsored",
     "publisher": "Zacks Small-Cap Research",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://nurexone.com/wp-content/uploads/2025/07/Zacks_SCR_Research_07092025_NRXBF_Sorensen.pdf",
     "state": "sourced",
     "title": "NRXBF: Test Results Show Spinal Injury Recovery"
    },
    {
     "date": "2025-03-01",
     "kind": "issuer-sponsored",
     "publisher": "Poschevale Securities",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://nurexone.com/wp-content/uploads/2025/04/Nurexone_Biologic_Inc_Poschevale_Report_March_2025_1743438611.pdf",
     "state": "sourced",
     "title": "NurExone Biologic Inc. research report"
    },
    {
     "date": "2024-07-01",
     "kind": "issuer-sponsored",
     "publisher": "Poschevale Securities",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://nurexone.com/wp-content/uploads/2024/08/Analyst-Report-on-NurExone.pdf",
     "state": "sourced",
     "title": "ExoPTEN"
    }
   ],
   "state": "found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [
    "Paragraph (o) of the definition",
    "Paragraph (q) of the definition"
   ],
   "outcomes": {
    "Paragraph (o) of the definition": {
     "determinable": true,
     "signal": "ACM-200"
    },
    "Paragraph (q) of the definition": {
     "determinable": true,
     "signal": "ACM-200"
    }
   },
   "read": {
    "basis": "one live read per instrument class, halt state and client category on this market; this issuer's group",
    "chapter": "https://mcp.ca-cm-kg.ai/book/aio.json",
    "door": "https://mcp.ca-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "rule_version": "acm-68000/ca/kyp-know-your-product-ni-31-103/r1",
   "section": "ca.aio.v11"
  },
  "record": {
   "as_of": "2026-11-06",
   "url": "https://mcp.ca-cm-kg.ai/record/TSXV/NRX",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://iiroc.mediaroom.com/index.php?s=2429&l=100",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:1e7079675e903e065894f84908781cd7ca26fa29793353cc4fc7240ed18b4966",
 "path": "/ca/TSXV/NRX",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is NurExone Biologic Inc., listed on the TSXV under ticker NRX. Its ISIN is CA67059R1091 and its LEI is 25490047UWNZ2P8ESB77. Its security type is Corporate, its sector is Life Sciences, and its jurisdiction is Ontario, Canada. Its segment is not on the record. Its listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 9 filings in the twelve months to 2026-11-06, on 9 filing days. Of these, 3 are exchange bulletins and 6 are newswire releases. The median gap between filing days is 10.5 days. The latest filing is dated 2026-10-30 and is a newswire release, 7 days before the record date. The exchange median is 19 days cadence, 9 filings and 17.0 days latency across 1427 TSXV issuers. The sector median is 17.5 days cadence, 7.0 filings and 14 days latency across 200 Life Sciences issuers.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor is not on the record, as none was found. Its location is not on the record. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting, name change, domicile change or segment move events. The issuer is listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "Under rule version acm-68000/ca/kyp-know-your-product-ni-31-103/r1, as of 2026-11-04, the outcome is determinable for both client categories. Paragraph (o) of the definition and paragraph (q) of the definition each carry signal ACM-200.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The issuer's investor-relations page names 7 research houses: Zacks Small Cap Research, Poschevale Securities, Tormont Group LLC, Fundamental Research Corp., Litchfield Hills Research LLC, Morningstar and WTR.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "The record holds 5 openly published research notes. Water Tower Research LLC published on 2026-05-21 and 2026-04-21. Zacks Small-Cap Research published on 2025-07-09. Poschevale Securities published on 2025-03-01 and 2024-07-01.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The market's vintage is not sealed. The record holds no sealed issuer years, and the market has no earliest sealed date. The live record began on 2026-09-10. The store holds sealed years 2021 through 2026 for this issuer, but these are not served as of a date, and the as-of answer is not_sealed.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "14 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.tsx.com/json/company-directory/search/tsxv/^*"
  },
  {
   "for": "identity.isin",
   "source": "https://www.marketscreener.com/quote/stock/NUREXONE-BIOLOGIC-INC-139971056/finances"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://api.gleif.org/api/v1/lei-records/25490047UWNZ2P8ESB77"
  },
  {
   "for": "identity.sector",
   "source": "https://www.tsx.com/en/resource/571"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.ca-cm-kg.ai/events/TSXV/NRX"
  },
  {
   "for": "the halt flag",
   "source": "https://iiroc.mediaroom.com/index.php?s=2429&l=100"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.ca-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://nurexone.com/investors/"
  },
  {
   "for": "open research",
   "source": "https://nurexone.com/wp-content/uploads/2026/05/NRX-Initiating-Coverage_-A-Novel-Exosome-Platform-at-the-Frontier-of-CNS-Regeneration-May-21-2026.pdf"
  },
  {
   "for": "open research",
   "source": "https://nurexone.com/wp-content/uploads/2026/04/MS_NRX-From-Preclinical-Promise-to-Clinical-Execution-De-Risking-the-Exosome-Opportunity-in-CNS-April-21-2026.pdf"
  },
  {
   "for": "open research",
   "source": "https://nurexone.com/wp-content/uploads/2025/07/Zacks_SCR_Research_07092025_NRXBF_Sorensen.pdf"
  },
  {
   "for": "open research",
   "source": "https://nurexone.com/wp-content/uploads/2025/04/Nurexone_Biologic_Inc_Poschevale_Report_March_2025_1743438611.pdf"
  },
  {
   "for": "open research",
   "source": "https://nurexone.com/wp-content/uploads/2024/08/Analyst-Report-on-NurExone.pdf"
  },
  {
   "for": "the record",
   "source": "https://mcp.ca-cm-kg.ai/record/TSXV/NRX"
  }
 ],
 "title": "NurExone Biologic Inc. (NRX) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}